Evidence map›Paper›PMID 31022184›Full record

ArticlePLoS genetics2019

Amino acid signatures of HLA Class-I and II molecules are strongly associated with SLE susceptibility and autoantibody production in Eastern Asians.

Julio E Molineros, Loren L Looger, Kwangwoo Kim, Yukinori Okada, Chikashi Terao, Celi Sun, Xu-Jie Zhou, Prithvi Raj, Yuta Kochi, Akari Suzuki and 23 more

Open access · goldAbstract read
In one paragraph

Article in PLoS genetics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 61 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. [Role of HLA genetic variants in autoimmune diseases].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

33 authors at 20 institutions in 5 countries.

Julio E MolinerosArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Loren L LoogerHoward Hughes Medical Institute, Janelia Research Campus, Ashburn, Virginia, United States of America.
Kwangwoo KimDepartment of Biology, Kyung Hee University, Seoul, Republic of Korea.ORCID 0000-0001-8926-6216
Yukinori OkadaDepartment of Statistical Genetics, Osaka University Graduate School of Medicine, Osaka, Japan.
Chikashi TeraoCenter for Genomic Medicine, Kyoto University Graduate School of Medicine, Kyoto, Japan.ORCID 0000-0002-6452-4095
Celi SunArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.
Xu-Jie ZhouRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Prithvi RajDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Yuta KochiLaboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Akari SuzukiLaboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Shuji AkizukiDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Shuichiro NakaboDepartment of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.ORCID 0000-0002-9250-1851
So-Young BangDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
Hye-Soon LeeDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.ORCID 0000-0002-8535-0442
Young Mo KangSchool of Medicine, Kyungpook National University Hospital, Daegu, Korea.
Chang-Hee SuhDepartment of Rheumatology, Ajou University Hospital, Suwon, Korea.ORCID 0000-0001-6156-393X
Won Tae ChungDong-A University Hospital, Department of Internal Medicine, Busan, Korea.ORCID 0000-0002-1585-1022
Yong-Beom ParkDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Jung-Yoon ChoeDepartment of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, Korea.
Seung-Cheol ShimDaejeon Rheumatoid & Degenerative Arthritis Center, Chungnam National University Hospital, Daejeon, Korea.
Shin-Seok LeeDepartment of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Korea.ORCID 0000-0001-6810-7355
Xiaoxia ZuoDepartment of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, China.
Kazuhiko YamamotoLaboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan.
Quan-Zhen LiDepartment of Immunology and Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Nan ShenDepartment of Rheumatology and Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Lauren L PorterHoward Hughes Medical Institute, Janelia Research Campus, Ashburn, Virginia, United States of America.ORCID 0000-0003-2031-8326
John B HarleyCenter for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.
Kek Heng ChuaDepartment of Biomedical Science, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Hong ZhangRenal Division, Peking University First Hospital, Peking University Institute of Nephrology, Key Laboratory of Renal Disease, Ministry of Health of China, Beijing, China.
Edward K WakelandDepartment of Immunology, University of Texas Southwestern Medical Center, Dallas, Texas, United States of America.
Betty P TsaoDivision of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, United States of America.ORCID 0000-0001-7938-5975
Sang-Cheol BaeDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.ORCID 0000-0003-4658-1093
Swapan K NathArthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, United States of America.ORCID 0000-0001-6013-9328
RIKEN Center for Integrative Medical Sciences · JPHanyang University Seoul Hospital · KROklahoma Medical Research Foundation · USThe University of Texas Southwestern Medical Center · USCincinnati Children's Hospital Medical Center · USHoward Hughes Medical Institute · USKyoto University · JPPeking University · CNAjou University Hospital · KRBroad Institute · USCentral South University · CNChonnam National University Hospital · KRChungnam National University Hospital · KRDaegu Catholic University · KRDong-A University Hospital · KRKyung Hee University · KRKyungpook National University Hospital · KRMedical University of South Carolina · USUniversity of Malaya · MYYonsei University · KR

Funding

HLA GENE COMPLEMENTATION IN PRIMARY SJOGREN'S AND LUPUSR01AI024717 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI KOTTYAN, LEAH CLAIRE, WEIRAUCH, MATTHEW TYSON · 1987 to 2025
$7.8M
Tissue Repository CoreP30AR070549 · NIAMS · CINCINNATI CHILDRENS HOSP MED CTR · PI Grant Sanford Schulert · 2016 to 2026
$7.7M
Gene Regulation as a Foundation for Autoimmune Disease PreventionU01AI130830 · NIAID · CINCINNATI CHILDRENS HOSP MED CTR · PI WEIRAUCH, MATTHEW TYSON · 2017 to 2021
$7.2M
Better Outcomes for Children: Promoting Excellence in Healthcare Genomics to Inform PolicyU01HG008666 · NHGRI · CINCINNATI CHILDRENS HOSP MED CTR · PI HARLEY, JOHN BARKER · 2015 to 2019
$4.2M
SLE Susceptibility and Clinical Significance at 2q22-24 across Multiple EthnicitiR01AR060366 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI NATH, SWAPAN K. · 2010 to 2019
$3.3M
Health Disparities and Genetic Architecture of Lupus in African AmericansR01MD007909 · NIMHD · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI NATH, SWAPAN K. · 2014 to 2018
$2.1M
Genetics of RASGRP1 & 3 in Lupus susceptibilityR21AR073941 · NIAMS · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI NATH, SWAPAN K. · 2018 to 2019
$423k
NHGRI NIH HHS U01 HG008666NIAID NIH HHS R01 AI024717NIAID NIH HHS U01 AI130830NIAMS NIH HHS P30 AR070549NIAMS NIH HHS R01 AR060366NIAMS NIH HHS R21 AR073941NIMHD NIH HHS R01 MD007909
6 · The paper itself

Abstract

Human leukocyte antigen (HLA) is a key genetic factor conferring risk of systemic lupus erythematosus (SLE), but precise independent localization of HLA effects is extremely challenging. As a result, the contribution of specific HLA alleles and amino-acid residues to the overall risk of SLE and to risk of specific autoantibodies are far from completely understood. Here, we dissected (a) overall SLE association signals across HLA, (b) HLA-peptide interaction, and (c) residue-autoantibody association. Classical alleles, SNPs, and amino-acid residues of eight HLA genes were imputed across 4,915 SLE cases and 13,513 controls from Eastern Asia. We performed association followed by conditional analysis across HLA, assessing both overall SLE risk and risk of autoantibody production. DR15 alleles HLA-DRB1*15:01 (P = 1.4x10-27, odds ratio (OR) = 1.57) and HLA-DQB1*06:02 (P = 7.4x10-23, OR = 1.55) formed the most significant haplotype (OR = 2.33). Conditioned protein-residue signals were stronger than allele signals and mapped predominantly to HLA-DRB1 residue 13 (P = 2.2x10-75) and its proxy position 11 (P = 1.1x10-67), followed by HLA-DRB1-37 (P = 4.5x10-24). After conditioning on HLA-DRB1, novel associations at HLA-A-70 (P = 1.4x10-8), HLA-DPB1-35 (P = 9.0x10-16), HLA-DQB1-37 (P = 2.7x10-14), and HLA-B-9 (P = 6.5x10-15) emerged. Together, these seven residues increased the proportion of explained heritability due to HLA to 2.6%. Risk residues for both overall disease and hallmark autoantibodies (i.e., nRNP: DRB1-11, P = 2.0x10-14; DRB1-13, P = 2.9x10-13; DRB1-30, P = 3.9x10-14) localized to the peptide-binding groove of HLA-DRB1. Enrichment for specific amino-acid characteristics in the peptide-binding groove correlated with overall SLE risk and with autoantibody presence. Risk residues were in primarily negatively charged side-chains, in contrast with rheumatoid arthritis. We identified novel SLE signals in HLA Class I loci (HLA-A, HLA-B), and localized primary Class II signals to five residues in HLA-DRB1, HLA-DPB1, and HLA-DQB1. These findings provide insights about the mechanisms by which the risk residues interact with each other to produce autoantibodies and are involved in SLE pathophysiology.

Indexed as

Amino Acid SequenceDisease SusceptibilityAllelesAmino Acid SubstitutionAsian PeopleAutoantibodiesFemaleGenetic Predisposition to DiseaseGenetic VariationHistocompatibility Antigens Class IHistocompatibility Antigens Class IIHumansLupus Erythematosus, SystemicMaleOdds RatioPolymorphism, Single NucleotideAutoantibodiesHistocompatibility Antigens Class IHistocompatibility Antigens Class II

Identifiers

PMID31022184
PMCPMC6504188
OpenAlexW2941757817

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.